A MULTICENTRE INTERVENTIONAL STUDY TO ASSESS BLOOD-BORNE VIRAL INFECTIONS IN BELGIAN PRISONS

Busschots D1,2, Kremer C3, Bielen R1,2, Koc OM1,2,4, Heyens L1,2,4, Brixko C5,6, Laukens P6, Orlent H6,7, Bilaey P6, De Smet F6, Hellemans G6, Muyldermans G8, Van Baalen L6, Hens N1,9, Van Vlierberghe H10, Robaeys G1,2,11

1Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium; 2Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium; 3Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-Biostat), Data Science Institute, Hasselt University, Diepenbeek, Belgium; 4School of NUTRIM, Maastricht University Medical Centre, Maastricht, the Netherlands; 5Department of Gastroenterology and Hepatology, CHR Citadelie, Liège, Belgium; 6Dienst Coördinatie Medische Zorg, Federale Overheidsdienst Justitie, Brussel, Belgium; 7Department of Gastroenterology and Hepatology, AZ St-Jan, Bruges, Belgium; 8Epidemiology and public health, Sciensano Brussels, Belgium; 9Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium; 10Department of Gastroenterology and Hepatology, UZ Gent, Gent, Belgium; 11Department of Gastroenterology and Hepatology, University Hospitals KU Leuven, Leuven, Belgium.

Background:
The prevalence of hepatitis C virus (HCV), hepatitis B virus and HIV infection among prisoners is often higher than in the general population. To date, there is no targeted screening in Belgian prisons. The study aimed to determine the prevalence of these infections in Belgian prisons using opt-in screening.

Methods:
A multicenter, interventional cohort study to assess the prevalence of HCV antibodies (Ab), hepatitis B surface antigen (HBsAg), and HIV (Ab and antigen) using opt-in screening was conducted in 11 prisons in Belgium between April 2019 and March 2020. Prisoners were tested using a finger prick, and risk factors were assessed using a questionnaire. A generalized linear mixed model was used to investigate the association between the various risk factors and prisoners with HCV.

Results:
Study uptake ranged from 16.9% to 35.4% and 886 prisoners were screened. Forty-four (5.0%) tested positive for HCV Ab, seven (0.8%) for HBsAg and two (0.2%) for HIV Ab. The prevalence of HCV RNA in the total cohort was 2.1% (19/886), of whom 9 (47.4%) were unaware of their infectious status. Thirteen (68.4%) prisoners were redirected for assessment for HCV treatment. HCV Ab risk factors were intravenous drug use (p = 0.004; aOR 11.5 CI 95% (2.6 – 88.7), ever used heroin (p = 0.003, aOR 6.4 CI 95% (1.9 – 24.7)) and more than 10 unsafe sexual contacts (p = 0.020; aOR 5.2 CI 95% (1.4 – 23.7)).

Conclusion:
Opt-in testing for viral hepatitis C, B, and HIV was relatively well-accepted. However, to avoid selection bias and get an overview of the total infected prison population in a country, we urge the need for systematic screening of all prisoners via opt-out. Mapping high-quality data is necessary to inform policymakers and the public health community.

Disclosure of Interest Statement: See example below:
D.B. has received travel grants from AbbVie and Gilead Sciences and research grants from Gilead; R.B. has received travel grants from AbbVie, Gilead Sciences and Merck Sharp & Dohme (MSD) and
research grants from Gilead and MSD; O.K. has received a travel grant from Gilead Sciences and his institution received research grants from Gilead Sciences and CyTuVax BV; C.B. has received travel grants from AbbVie and Gilead Sciences; N.H. has received grants from GlaxoSmithKline (GSK), Johnson & Johnson pharmaceuticals and Pfizer; H.V.V has not received grants, but the department has received grants from Gilead, Janssen Pharmaceuticals, Roche, Abbvie, Merck, Falk, Ferring, Bayer; G.R. has received research grants from AbbVie, Janssen Pharmaceuticals, MSD, and consultancy agreements for AbbVie, BMS, Gilead Sciences and MSD. All other co-authors report no competing interests.